Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Immunol.

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1669840

Corrigendum: The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection

Provisionally accepted
Ning PengNing Peng1Lin-Feng MaoLin-Feng Mao1Jia-Yong SuJia-Yong Su2Shao-Ping LiuShao-Ping Liu3Jun-Jie OuJun-Jie Ou4Shu-Chang ChenShu-Chang Chen4Ze SuZe Su5Wen-Feng LiWen-Feng Li6Fu-Quan YangFu-Quan Yang7Yong-Heng ZhouYong-Heng Zhou1Le LiLe Li2Jian-Hong ZhongJian-Hong Zhong2*
  • 1First Affiliated Hospital, Guangxi Medical University, Nanning, China
  • 2Guangxi Medical University Cancer Hospital, Nanning, China
  • 3Guigang City People's Hospital, Guigang, China
  • 4The People’s Hospital of Wuzhou, Wuzhou, China
  • 5First Peoples Hospital of Nanning, Nanning, China
  • 6The First People’s Hospital of Yulin, Yulin, China
  • 7The First People's Hospital of Yulin, Yulin, China

This article is a correction to:

  1. The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection

    1. Read original article

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

Corrigendum on: Peng N, Mao L-F, Su J-Y, Liu S-P, Ou J-J, Chen S-C, Su Z, Li W-F, Yang F-Q, Zhou Y-H, Li L and Zhong J-H (2025) The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection. Front. Immunol. 16:1593153. doi: 10.3389/fimmu.2025.1593153 In the published article, there was an error in Supplementary Tables 1 and2. Several units and the order in which the baseline variables appear are written incorrectly. The correct material statement appears below. The red font represents the modified content. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated. 1. In the published article, there was an error. In the abstract, the hazard ratio of 1.46 was erroneous due to a typographical mistake. The accurate hazard ratio value is 1.046.

Keywords: Hepatocellular Carcinoma, high-risk of recurrence, tislelizumab, Recurrence-free survival, adjuvant therapy

Received: 20 Jul 2025; Accepted: 08 Aug 2025.

Copyright: © 2025 Peng, Mao, Su, Liu, Ou, Chen, Su, Li, Yang, Zhou, Li and Zhong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Jian-Hong Zhong, Guangxi Medical University Cancer Hospital, Nanning, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material